How Site Location Influences Diversity in Clinical Trial Enrollment

Introduction: The Link Between Geography and Inclusion

Diversity in clinical trial enrollment is now a regulatory priority, a scientific necessity, and an ethical obligation. Yet, one of the most overlooked factors influencing diversity is site location. Where a trial is conducted has a direct impact on who has access to participate. Sponsors that select sites in non-diverse or high-barrier regions often fail to recruit a representative population, leading to biased outcomes and delayed regulatory approval.

This article explores the critical role of site geography in fostering or hindering diverse patient enrollment and outlines actionable strategies to align location planning with diversity, equity, and inclusion (DEI) goals.

1. Understanding Diversity Metrics in Clinical Trials

Diversity in clinical research encompasses several dimensions:

• Race and Ethnicity (e.g., African American, Asian, Hispanic/Latino)
• Age (e.g., inclusion of elderly and pediatric populations)
• Sex and Gender
• Socioeconomic Status (access to care, insurance, housing)
• Geography (urban vs rural, regionally underserved populations)

Site location influences nearly all of these, especially in relation to race, ethnicity, and socioeconomic access.

2. Regulatory Landscape on Enrollment Diversity

Regulatory agencies have introduced policies and expectations around inclusive recruitment:

• FDA Diversity Plan Requirement (2022): Requires plans for achieving demographic representation aligned with disease epidemiology
• ICH E8(R1): Advocates for generalizability of results and fair subject selection
• EMA Reflection Paper: Emphasizes underrepresented population inclusion in pivotal trials

Failure to meet diversity expectations can trigger post-marketing requirements or even rejection of marketing applications.

3. How Site Location Drives Enrollment Patterns

Demographic data is highly clustered geographically. Choosing sites in homogenous or affluent regions inadvertently excludes significant portions of the population. Consider the following comparison:

Sponsors targeting enrollment diversity must therefore select site locations where minority populations reside and receive care.

4. Geographic Barriers to Enrollment

Site location can impose the following participation barriers:

• Distance from minority-majority communities
• Lack of public transport to site
• Trial awareness gaps in underserved areas
• Trust and engagement deficits in historically excluded communities
• Lack of culturally or linguistically competent site staff

These must be accounted for during feasibility and startup planning.

5. Using Census and Epidemiologic Data to Guide Site Location

Sponsors can use public datasets to align site planning with diversity goals:

• US Census Data: Demographic distribution by ZIP code
• CDC’s Social Vulnerability Index (SVI): Community risk stratification
• WHO Health Equity Data: Country-level access and outcomes by demographics
• Historic trial enrollment data from ClinicalTrials.gov

Example: A sponsor used SVI data to select six oncology sites in high-vulnerability ZIP codes and saw a 38% increase in non-white enrollment over the prior protocol.

6. Community and Safety-Net Site Partnerships

Instead of relying only on academic medical centers, sponsors should partner with:

• Federally Qualified Health Centers (FQHCs)
• Veterans Affairs (VA) clinics
• Community hospitals and non-profit health systems
• Faith-based health organizations

These locations are embedded in underserved communities and offer trust and access that large academic centers may lack.

7. Decentralized Trials and Mobile Locations

When traditional sites in diverse areas are unavailable, sponsors can deploy:

• Mobile research units for outreach in minority neighborhoods
• Remote visits with home health support
• Telemedicine for screening and consent
• Community center-based pop-up trial sites

These models lower the geographic barrier and bring trials directly to patients.

8. Diversity Feasibility Scorecard

Site feasibility teams should include diversity scoring in their evaluations:

Sites with low scores may be deprioritized unless diversity mitigation plans are established.

Conclusion

Site location is a determinant of diversity—not just an operational variable. Geographic placement determines who hears about the trial, who can access it, and who completes it. Sponsors committed to inclusive trials must strategically plan site networks using census and epidemiological data, community partnerships, decentralized modalities, and targeted outreach in underserved regions. Diversity by design begins with geography, and success depends on embedding these principles into site feasibility from the start.

Leveraging AI to Promote Diversity in Clinical Trial Recruitment

Why Diversity Matters in Clinical Trials

Diversity in clinical trials isn’t just about fairness—it’s a scientific and regulatory requirement. Lack of representation from racial, ethnic, socioeconomic, gender, and age-diverse populations can lead to biased outcomes and limit the generalizability of trial results. Regulatory agencies such as the FDA and EMA are increasingly mandating inclusion of underrepresented groups as part of approval conditions.

However, traditional recruitment methods often fall short in reaching diverse populations due to systemic barriers such as language, geography, health literacy, mistrust, and technological access. AI is now being harnessed to address these barriers by identifying, engaging, and enrolling a more representative patient population using automation, language processing, and predictive analytics.

Using NLP to Analyze Demographic Gaps in EMR Data

Natural Language Processing (NLP) enables automated extraction of structured and unstructured demographic data from electronic medical records (EMRs). This helps sites and sponsors identify diversity gaps by race, ethnicity, language preference, and other social determinants of health (SDOH).

• ✅ Example: An oncology trial in the U.S. used NLP to analyze 500,000 EMRs and found a 28% underrepresentation of Hispanic patients based on zip code–matched census data.
• 📉 Action: The recruitment strategy was adapted with Spanish-language chatbot outreach in high-density Hispanic areas.
• 🛠 Integration: This data fed directly into the site feasibility matrix within their CTMS platform.

This approach aligns with diversity reporting requirements recommended in the FDA’s Draft Guidance on Diversity Plans.

AI-Powered Outreach to Underserved Populations

AI tools are also being used to create and deliver culturally adapted outreach messages to specific populations. These include automated ad targeting, SMS campaigns, and AI chatbots that adjust their tone, language, and visual content based on community preferences. This dynamic personalization improves trust and participation among historically excluded groups.

• 📱 Use Case: A decentralized vaccine trial used AI to deliver 75,000 culturally relevant messages in 6 languages across 3 states.
• 🤝 Impact: Participation among Black and Hispanic populations improved by 49% compared to previous studies in the same region.
• 🔒 Data Handling: Tools used HIPAA-compliant APIs and opt-in mechanisms to ensure data protection.

AI-based outreach tools also leverage geofencing and digital behavioral signals to increase the likelihood of identifying receptive populations in real time.

Machine Learning Models for Bias Detection and Mitigation

Another critical application of AI is detecting and mitigating bias in recruitment algorithms and processes. AI models trained on biased historical data can perpetuate inequity unless proactively monitored. Tools now exist to audit AI decision paths and apply fairness constraints to ensure equitable outreach and eligibility assessments.

• 📊 Example: A sponsor deploying automated protocol matching introduced demographic balance thresholds to prevent oversampling from dominant groups.
• 🧠 Result: The adjusted AI model achieved a 36% increase in enrollment diversity without reducing enrollment speed.
• ⚙️ Monitoring: The AI model underwent quarterly fairness audits using external benchmark datasets and bias quantification indices.

These techniques are increasingly included in technology validation packages and ethics submissions to Institutional Review Boards (IRBs).

AI-Enhanced Eligibility Matching for Diverse Populations

Eligibility matching algorithms often filter out underrepresented populations due to rigid inclusion/exclusion criteria. AI tools now allow dynamic inclusion algorithms that simulate protocol adaptations, recommend eligibility adjustments, or apply flexible thresholds based on SDOH data to increase participation of marginalized groups.

• 💻 Platform: Several CTMS vendors now offer AI-enhanced eligibility engines as a module.
• 📋 Real World Case: A cardiovascular trial increased representation of rural elderly patients by 41% using AI-informed protocol amendments.
• ⚡ Risk Mitigation: All changes were linked to risk-based monitoring triggers and FDA pre-submission consultations.

This approach is especially powerful in early-phase trials, where exploratory subpopulation insights are critical for dose optimization and safety monitoring.

AI Diversity Dashboards for Ongoing Monitoring

Real-time dashboards are being developed using AI to track and visualize diversity metrics throughout the recruitment process. These dashboards pull data from multiple sources—EMRs, EDCs, eConsent systems—and apply analytics to generate heatmaps, risk scores, and alerts for non-representative enrollment trends.

• 📈 KPI Tracking: Dashboards show enrollment by race/ethnicity/gender versus study targets.
• 🔔 Alerts: Triggered when disparity exceeds a pre-set threshold (e.g., 15% deviation from census match).
• 🤔 Compliance: Dashboards align with FDA and EMA guidance for inclusive recruitment plans.

These dashboards not only support regulatory compliance but also enable early corrective actions that improve long-term study viability and ethical transparency.

Conclusion

AI tools are unlocking new possibilities in diversifying patient recruitment across the clinical trial landscape. From NLP-based demographic analyses to machine learning-driven outreach and fairness monitoring, these innovations are helping ensure that clinical trials better reflect the populations they intend to serve. Successful deployment requires not just technical capability but careful ethical design, regulatory integration, and community engagement. As the industry moves toward more inclusive science, AI will be a critical enabler of that transformation.

References:

• FDA Guidance on Diversity Plans in Clinical Trials
• ICH E8(R1) – General Considerations for Clinical Studies
• PharmaGMP.in – GxP in Inclusive Research
• PharmaValidation.in – Validating AI Tools in Clinical Recruitment